Dipartimento di Medicina Clinica e delle Patologie Emergenti, University of Palermo, Italy.
Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):1077-87. doi: 10.1177/039463200902200424.
Eosinophil count in nasal fluid (ECNF) was used to differentiate nasal pathologies. Receiver operating characteristic (ROC) curve analysis and the area under the curve (AUC) were performed to evaluate the ECNF's accuracy in distinguishing allergic rhinitis (AR) from non-allergic rhinitis (NAR). We also evaluated the accuracy of ECNF in recognizing patients with mild and severe symptoms of rhinitis and patients with ineffective and effective clinical responses to antihistamines. 1,170 consecutive adult patients with a clinical history of rhinitis were studied. ECNF's median in AR was 6.0 and 2.0 in NAR and the best cut-off value was > 3.0, AUC = 0.75. ECNF's median in AR with mild nasal symptoms was 3.0 and 7.0 with severe symptoms, and the best cut-off value was 4.0, AUC = 0.90. ECNF's median in NAR with mild nasal symptoms was 2.0 and 8.5 with severe symptoms, and the best cut-off value was > 4.0, AUC = 0.86. ECNF's median in AR with effective clinical response to antihistamines was 4.0 and 8.0 with ineffective response, the best cut-off value was < or = 5.0, AUC = 0.94. ECNF's median in NAR with an effective clinical response to antihistamines was 1.0 and 2.0 with ineffective response, and the best cut-off value was < or = 3.0, AUC = 0.64. Our results suggest an interesting practical use of ECNF data as evaluator of the clinical severity both AR and NAR. As predictor of the clinical response to antihistamines, ECNF is accurate only in patients with AR. The ECNF's performance was moderately accurate in distinguish patients with AR and NAR.
鼻液嗜酸粒细胞计数 (ECNF) 用于区分鼻腔病变。进行了接收者操作特征 (ROC) 曲线分析和曲线下面积 (AUC) 以评估 ECNF 在区分变应性鼻炎 (AR) 和非变应性鼻炎 (NAR) 中的准确性。我们还评估了 ECNF 识别鼻炎症状轻、重患者和抗组胺治疗临床反应无效、有效的患者的准确性。对 170 例连续成年鼻炎患者进行了研究。AR 患者的 ECNF 中位数为 6.0，NAR 为 2.0，最佳截断值> 3.0，AUC = 0.75。AR 患者轻度鼻症状的 ECNF 中位数为 3.0，重度症状为 7.0，最佳截断值为 4.0，AUC = 0.90。AR 患者轻度鼻症状的 ECNF 中位数为 2.0，重度症状为 8.5，最佳截断值为> 4.0，AUC = 0.86。AR 患者抗组胺治疗临床反应有效的 ECNF 中位数为 4.0，无效的为 8.0，最佳截断值为≤ 5.0，AUC = 0.94。NAR 患者抗组胺治疗临床反应有效的 ECNF 中位数为 1.0，无效的为 2.0，最佳截断值为≤ 3.0，AUC = 0.64。我们的结果表明，ECNF 数据可作为评估 AR 和 NAR 临床严重程度的一种实用工具。作为抗组胺治疗临床反应的预测指标，ECNF 仅在 AR 患者中准确。ECNF 在区分 AR 和 NAR 患者方面的性能为中度准确。
